Comparative Pharmacology
Head-to-head clinical analysis: DUZALLO versus ULORIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DUZALLO versus ULORIC.
DUZALLO vs ULORIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
DUZALLO (allopurinol) is a xanthine oxidase inhibitor that reduces uric acid production by inhibiting the conversion of hypoxanthine to xanthine and xanthine to uric acid.
ULORIC (febuxostat) is a xanthine oxidase inhibitor that reduces serum uric acid levels by inhibiting the enzyme xanthine oxidase, which catalyzes the conversion of hypoxanthine to xanthine and xanthine to uric acid.
Adults: 200 mg orally twice daily.
40 mg orally once daily; may increase to 80 mg once daily if serum uric acid not at target after 2 weeks.
None Documented
None Documented
Terminal elimination half-life is approximately 12 hours (range 10–14 hours), allowing twice-daily dosing for steady-state achievement within 2–3 days.
Terminal elimination half-life is approximately 5-8 hours. This short half-life supports once-daily dosing for maintenance of therapeutic urate-lowering effect.
Primarily renal excretion (approximately 70% as unchanged drug); biliary/fecal excretion accounts for about 20%; the remainder undergoes hepatic metabolism.
Renal excretion of unchanged drug accounts for approximately 40-45% of the dose. Biliary/fecal excretion eliminates about 50-55% of the dose, primarily as oxidative metabolites.
Category C
Category C
Xanthine Oxidase Inhibitor
Xanthine Oxidase Inhibitor